Fast Five Quiz: Relapsing-Remitting Multiple Sclerosis Management

Christopher Luzzio, MD; Kerstin Hellwig, MD


June 30, 2022

Immunomodulating drugs approved for RRMS reduce clinical relapses and slow the rate of disability progression. No DMT cures MS or heals old lesions. Their potential to reduce long-term disability is being investigated. Some studies suggest a decreased long-term risk for MS disease progression with newer agents, particularly the monoclonal antibody DMTs.

Learn more about the management of RRMS.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.